oshad.ru


MRNA ANALYST RATINGS

Analyst Ratings. Sell; Under; Hold; Over; Buy. Number of Ratings 25 Full Ratings. Recent News. MarketWatch. Dow Jones. Read full story · Moderna Inc. stock. Moderna stock has received a consensus rating of hold. The average rating score is and is based on 16 buy ratings, 25 hold ratings, and 8 sell ratings. What was. Moderna's activity chart (see below) currently has price targets and ratings on display. The stock rating distribution of MRNA is % BUY, %. Analyst Ratings of MODERNA INC(NASDAQ:MRNA) stock. Analyst ratings, forecast, price target, upgrades and downgrades. 26 analyst ratings · buy 50% · hold 38% · sell 12%.

The analyst firm set a price target for expecting MRNA to fall to within 12 months (a possible % downside). 27 analyst firms have reported ratings. Moderna, Inc. analysts consensus, targets, ratings and recommendations | Nasdaq: MRNA | Nasdaq. See Moderna, Inc. (MRNA) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. What is the target price for Moderna (MRNA)?The latest price target for Moderna (NASDAQ: MRNA) was reported by Deutsche Bank on November 2, Moderna Analyst Ratings ; Total Analysts. 16 ; Consensus Rating. Hold ; Price Target. $ ; Upside. +%. Based on short-term price targets offered by 17 analysts, the average price target for Moderna comes to $ The forecasts range from a low of $ to a. Moderna Inc. research and ratings by Barron's. View MRNA %. Analyst Ratings. Average price target from 25 ratings: $ Analyst Ratings. 3M Ago1M Ago. According to 7 Wall Street analysts that have issued a 1 year MRNA price target, the average MRNA price target is $, with the highest MRNA stock price. The average analyst rating for Moderna stock from 15 stock analysts is "Hold". This means that analysts believe this stock is likely to perform similarly to the. Ratings values: · Strong Buy = 5 · Moderate Buy = 4 · Hold = 3 · Moderate Sell = 2 · Strong Sell = 1.

MRNA | Complete Moderna Inc. stock news by MarketWatch. View real-time stock prices and stock Analyst Ratings. Sell; Under; Hold; Over; Buy. Number of Ratings. Based on analysts offering 12 month price targets for MRNA in the last 3 months. The average price target is $ with a high estimate of $ and a low. While ratings are subjective and will change, the latest Moderna (MRNA) rating was a downgraded with a price target of $ to $ The current price. Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that. Moderna (MRNA) has a Smart Score of 4 based on an analysis of 8 unique data sets, including Analyst Recommendations, Crowd Wisdom, and Hedge Fund Activity. The Trend in the Broker Recommendations MRNA's average broker recommendation rating improved by over the prior 16 months. The points below can provide you. The consensus rating for Moderna is Hold while the average consensus rating for medical companies is Moderate Buy. Learn more on how MRNA compares to other. Mean consensus. OUTPERFORM ; Number of Analysts. 27 ; Last Close Price. USD ; Average target price. USD ; Spread / Average Target. +%. Analyst Ratings ; 3M Ago1M AgoCurrent ; Buy. 9 ; Overweight. 2. 1. 1.

The company's average rating score is , and is based on 5 buy ratings, 8 hold ratings, and 2 sell ratings. Price Target Upside/Downside. According to. Moderna Inc. analyst ratings, historical stock prices, earnings estimates & actuals. MRNA updated stock price target summary. Moderna Inc's average analyst rating is Buy. Stock Target Advisor's own stock analysis of Moderna Inc is Slightly Bullish, which is based on 9 positive. Based on 25 analysts giving stock ratings to MRNA in the past 3 months. Neutral. SellBuy. Strong sellStrong buy. Moderna, Inc.'s stock symbol is MRNA and currently trades under NASDAQ. It's current price per share is approximately $

Moderna stock upgraded to outperform by Oppenheimer \u0026 Co

down jones historical data | bld stock

17 18 19 20 21

Copyright 2013-2024 Privice Policy Contacts